Glucocorticoid replacement is associated with hypertriglyceridaemia, elevated glucose and higher non-HDL cholesterol and may diminish the association of HDL cholesterol with the-629C > A CETP promoter polymorphism in GH-receiving hypopituitary patients

Robin P. F. Dullaart*, Jeroen L. Schols, Gerrit van der Steege, Peter M. J. Zelissen, Wim J. Sluiter, Andre P. van Beek

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

13 Citations (Scopus)

Abstract

Objectives The effect of glucocorticoid substitution on the prevalence of metabolic syndrome components (NCEP ATP III criteria) and serum lipid levels was determined in GH-replaced hypopituitary patients. As glucocorticoid replacement is associated with a pronounced decrease in plasma cholesteryl ester transfer protein (CETP) activity, we also tested associations of HDL cholesterol with the -629C > A CETP promoter polymorphism in subjects with and without ACTH deficiency.

Design and patients In a university setting, we retrieved protocolized clinical and laboratory data from 165 adult hypopituitary patients, who had received GH for 1 year.

Results After adjustment for age, sex and smoking, non-HDL cholesterol (P = 0.05) and triglycerides (P = 0.004) were higher, but HDL cholesterol was not decreased in 117 glucocorticoid (mainly cortisone acetate in two divided doses) receiving subjects compared to 48 ACTH-sufficient subjects. The prevalence of elevated plasma glucose and/or diabetes (P = 0.04) and hypertriglyceridaemia (P = 0.005), but not of other metabolic syndrome components, was higher in glucocorticoid-replaced subjects. HDL cholesterol was higher in -629 A allele carriers compared to -629CC homozygotes in ACTH-sufficient subjects (P = 0.04), but not in glucocorticoid-treated subjects (P = 0.13). Multiple linear regression analysis demonstrated that only in ACTH-sufficient subjects, HDL cholesterol was independently related to this CETP gene variation (P = 0.03).

Conclusions In GH- and glucocorticoid-replaced hypopituitary patients, serum non-HDL cholesterol and triglycerides are higher and the prevalence of hyperglycaemia is increased, but HDL cholesterol is not decreased. Conventional glucocorticoid replacement appears to diminish the association of HDL cholesterol with a common CETP gene variation.

Original languageEnglish
Pages (from-to)359-366
Number of pages8
JournalClinical Endocrinology
Volume69
Issue number3
DOIs
Publication statusPublished - Sept-2008

Keywords

  • ESTER TRANSFER PROTEIN
  • DENSITY-LIPOPROTEIN CHOLESTEROL
  • GROWTH-HORMONE-DEFICIENT
  • CARDIOVASCULAR RISK
  • CUSHINGS-SYNDROME
  • PREMATURE MORTALITY
  • METABOLIC SYNDROME
  • LIPOLYTIC ENZYMES
  • HEALTHY-MEN
  • DISEASE

Fingerprint

Dive into the research topics of 'Glucocorticoid replacement is associated with hypertriglyceridaemia, elevated glucose and higher non-HDL cholesterol and may diminish the association of HDL cholesterol with the-629C > A CETP promoter polymorphism in GH-receiving hypopituitary patients'. Together they form a unique fingerprint.

Cite this